# SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

> **NCT07560566** · PHASE2 · RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Hepato Cellular Carcinoma (HCC)
- Hand Foot Skin Syndrome

## Interventions

- **DRUG:** Topical Indomethacin

## Key facts

- **NCT ID:** NCT07560566
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-09
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07560566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07560566, "SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07560566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*